Trilaciclib dihydrochloride is a kinase inhibitor indicated to decrease the frequency of chemotherapy-induced myelosuppression in adults receiving certain types of chemotherapy. By transiently inhibiting… Read more
Trilaciclib dihydrochloride is a kinase inhibitor indicated to decrease the frequency of chemotherapy-induced myelosuppression in adults receiving certain types of chemotherapy. By transiently inhibiting cyclin-dependent kinases 4 and 6, this agent helps protect hematopoietic stem cells and immune system progenitors from cytotoxic damage. Accurate analytical characterization of this compound requires high-quality reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical laboratories rely on these reference materials for comprehensive impurity profiling, method development, and validation of analytical procedures such as HPLC and LC-MS. Utilizing certified standards ensures consistency in monitoring drug purity and degradation products throughout the manufacturing and stability testing processes. These essential materials facilitate precise quantification and identification, supporting stringent quality control protocols necessary for regulatory compliance and the maintenance of product safety standards in drug development.